You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Resistant to anti-EGFR

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (cetuximab (CTX) or nimotuzumab (NTZ))

Completed
  • Nasopharyngeal Carcinoma
  • cetuximab (CTX) or nimotuzumab (NTZ)
  • Shanghai, China
    Xiaoshen Wang
Mar 23, 2022

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • (no location specified)
Oct 31, 2023

NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

Recruiting
  • NSCLC
  • EGFR Gene Mutation
  • neo-antigen vaccine
  • Nanjing, China
    The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023

NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

Not yet recruiting
  • NSCLC
  • Oral S-1 + Oral Osimertinib
  • Singapore, Singapore
    National Cancer Center Singapore
Mar 6, 2023

Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))

Completed
  • Colorectal Cancer Metastatic
  • C-met Overexpression
  • Tivantinib (ARQ197)
  • Rozzano, Milano, Italy
    Istituto Clinico Humanitas
Sep 8, 2022

Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III

Terminated
  • Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
  • +9 more
  • Bintrafusp Alfa
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 4, 2022

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

Adenocarcinoma of the Stomach Trial in Goyang (Anti-EGFR antibody in combination with weekly paclitaxel)

Recruiting
  • Adenocarcinoma of the Stomach
  • Anti-EGFR antibody in combination with weekly paclitaxel
  • Goyang, Gyeonggi, Korea, Republic of
    National Cancer Center
Nov 29, 2022

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Trial in Charlottesville (EGFR BATs after

Recruiting
  • Locally Advanced Pancreatic Adenocarcinoma
  • Metastatic Pancreatic Adenocarcinoma
  • EGFR BATs after standard of care chemo
  • Charlottesville, Virginia
    University of Virginia
Mar 30, 2022

HLX07, nsqNSCLC, High EGFR Expression Trial in Shanghai (HLX07+carboplatin+pemetrexed, HLX07+docetaxel, HLX07)

Not yet recruiting
  • HLX07, nsqNSCLC, High EGFR Expression
  • Shanghai, China
    Shanghai Chest Hospital
Jul 5, 2022

Migraine Trial in Talavera De La Reina (Transcranial direct current stimulation (tDCS), anti-CGRP-mAbs)

Completed
  • Migraine
  • Talavera De La Reina, Toledo, Spain
    Clinica de Intervencion en Neurociencias
Oct 15, 2023

Advanced Solid Tumors Trial in Shanghai (HLX07+Gemcitabine+Cisplatin, HLX07+Paclitaxel+Carboplatin, HLX07+mFOLFOX6)

Active, not recruiting
  • Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Shanghai East Hospital
May 5, 2022

NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

Not yet recruiting
  • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
  • MCLA-129: 1500mg or 2000mg IV Q2W
  • Befotertinib: 75 mg or 100 mg Po QD
  • Bengbu, Anhui, China
  • +2 more
Aug 28, 2023

Non Small Cell Lung Cancer Trial in Shanghai (Tislelizumab, Carboplatin, Pemetrexed)

Recruiting
  • Non Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 19, 2021

Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR

Completed
  • Metastatic Colorectal Adenocarcinoma
    • (no location specified)
    Oct 9, 2023

    Metastatic Colorectal Cancer Trial in Madison (Panitumumab, Cetuximab, Irinotecan)

    Recruiting
    • Metastatic Colorectal Cancer
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Sep 13, 2022

    Prostate Cancer Trial in Beijing, Nanjing (QLH12016)

    Not yet recruiting
    • Prostate Cancer
    • Beijing, Beijign, China
    • +1 more
    Jul 25, 2023

    Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

    Not yet recruiting
    • Nephrotic Syndrome
    • Genova, Italy
      IRCCS G. Gaslini
    Jan 19, 2023

    Metastatic Castration Resistant Prostate Cancer Trial in London (IMU-935)

    Recruiting
    • Metastatic Castration Resistant Prostate Cancer
    • London, United Kingdom
      Institute of Cancer Research
    Jan 31, 2023

    Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

    Not yet recruiting
    • Lung Adenocarcinoma
    • +3 more
    • Serplulimab and Bevacizumab injection
    • (no location specified)
    Dec 21, 2022

    A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • +4 more
      • Guangzhou, Guangdong, China
        Cancer Center, Sun Yat-sen University
      Oct 25, 2022